New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma. Cancers (Basel) 2023 Dec 08;15(24)
Date
12/23/2023Pubmed ID
38136295Pubmed Central ID
PMC10741466DOI
10.3390/cancers15245749Scopus ID
2-s2.0-85180705236 (requires institutional sign-in at Scopus site) 1 CitationAbstract
The incidence of hepatocellular carcinoma (HCC) has been increasing over the past decades, but improvements in systemic and locoregional therapies is increasing survival. Current locoregional treatment options include ablation, transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and stereotactic body radiotherapy (SBRT). There is ongoing research regarding the combination of systemic and local therapies to maximize treatment effect as well as in new non-invasive, image-guided techniques such as histotripsy. There is also active research in optimizing the delivery of therapy to tumors via nanostructures and viral-vector-mediated gene therapies. In many cases, patients require a combination of therapies to achieve tumor control and prolong survival. This article provides an overview of the most common liver-directed therapies for HCC as well as insight into more recent advances in personalized medicine and emerging techniques.
